Skip Navigation

European Heart Journal 2008 29(4):427-428; doi:10.1093/eurheartj/ehm610
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vanhoutte, D.
Right arrow Articles by Heymans, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanhoutte, D.
Right arrow Articles by Heymans, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Factor XIII: the cement of the heart after myocardial infarction?

Davy Vanhoutte1 and Stephane Heymans2,*

1 Center for Transgene Technology and Gene Therapy and Department of Cardiology, University of Leuven, Belgium
2 Cardiovascular Research Institute Maastricht, Department of Cardiology, P debeyelaan 25, 6202 AZ, Maastricht, The Netherlands

* Corresponding author. Tel: +31 43 3882949, Fax: +31 43 3871055, Email: s.heymans@cardio.unimaas.nl

This editorial refers to ‘Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction’ by M. Nahrendorf et al.,{dagger} on page 445

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

Heart failure (HF) affects >11 million people in the USA and Europe, and ischaemic heart disease accounts for >60% of these patients.1 Despite excellent diagnostic and therapeutic standards for myocardial infarction (MI), improved early phase imaging and therapy are essential to prevent the progression of cardiac dilatation and dysfunction after acute MI.

Transglutaminases (TGs) are a widely distributed group of eight isoenzymes, comprising factor XIII (FXIII) and TG type 1–type 7. They catalyse the post-translational . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction
Matthias Nahrendorf, Elena Aikawa, Jose-Luiz Figueiredo, Lars Stangenberg, Susanne W. van den Borne, W. Matthijs Blankesteijn, David E. Sosnovik, Farouc A. Jaffer, Ching-Hsuan Tung, and Ralph Weissleder
EHJ 2008 29: 445-454. [Abstract] [FREE Full Text]